By
admin
#americanindian, #Analysis, #article_normal, #BioNTech, #BioNTech SE ADR, #Biopharmaceuticals, #Biotechnology, #bivalentbooster, #BNTX, #booster, #C&E Industry News Filter, #Content Types, #Corporate, #Corporate/Industrial News, #COVID19, #data, #epidemics, #Factiva Filters, #Fresh, #general news, #government policy, #Health, #Health Care, #Immunizations, #industrial news, #Infectious Diseases, #Medical Conditions, #medical treatments, #Medical Treatments/Procedures, #medications, #nativealaskan, #Novavax Inc., #Novel Coronaviruses, #NVAX, #omicron, #outbreaks, #Outbreaks/Epidemics, #PFE, #Pfizer, #Pfizer Inc., #Pharmaceuticals, #Political, #Political/General News, #Procedures, #regulation, #Regulation/Government Policy, #Respiratory Tract Diseases, #Results, #Retail, #Retail/Wholesale, #shows, #specialized drugs, #Specialized Drugs/Medications, #strong, #sublineages, #Updated, #Vaccines, #Wholesale, #Wholesalers
A fresh analysis of data on the immune response generated by the bivalent COVID-19 booster showed strong results against the newer omicron sublineages, Pfizer and German partner BioNTech said Friday.
The bivalent booster targets the BA.4 and BA.5 omicron variants as well as the original virus, and it also appears to be effective against the sublineages dubbed BA.4.6, BA.2.75.2, BQ.1.1 and XBB.1.
The…
